Abstract
Background: A prospective study was performed to assess standard uptake value (SUV)-level based 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) lymph node staging in 33 patients with oropharyngeal squamous cell cancer (OSCC) out of a total of 99 patients with head-and-neck squamous cell cancer (HNSCC) and the role of nodal molecular marker expression in diagnostic outcome prediction. Methods: Preoperative nodal PET/CT staging in 123 lymph nodes was correlated with postoperative lymph node histology, which served as gold standard. Tissue samples were prepared for immunohistochemistry of the excised lymph nodes. Results: The negative and positive predictive values (NPV and PPV) of PET for correct lymph node assessment were 100% and 93%, respectively. There was a significant association between SUVmax and lymph node histology (p < 0.0001) and a significant linear correlation between SUVmax and nodal size (Pearson's correlation coefficient r = 0.61336, p < 0.0001). The molecular marker E-Cadherin was significantly overexpressed in lymph node metastases (p < 0.0001). Benign lymph nodes showed significant 2-fold Bcl2 overexpression (p < 0.0001). However, the molecular marker expression profiles were inhomogeneous and did not allow valuable diagnostic outcome prediction. Conclusions: SUV level-based 18F-FDG-PET/CT lymph node assessment in OSCC still has to be considered as the most established and reliable staging tool. Lymph node molecular marker expression profiles need to be investigated further as they currently do not sufficiently contribute to therapy decision-making.
Journal Section:
Original Article
References
1.
Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, Dusing RW, Machtay M: FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010;2:1-7.
[PubMed]
2.
Yamazaki Y, Saitoh M, Notami K, Tei K, Totsuka Y, Takinami S, Kanegae K, Inubushi M, Tamaki N, Kitagawa Y: Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 2008;22:177-184.
[PubMed]
3.
Elsheik MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A: Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 2006;28:842-849.
[PubMed]
4.
Rothenberg SM, Ellisen LW: The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 2012;122:1951-1957.
[PubMed]
5.
Denaro N, Russi EG, Colantonio I, Adamo V, Merlano MC: The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology 2012;83:108-116.
[PubMed]
6.
Sadick M, Schoenberg SO, Hoermann K, Sadick H: [Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer]. Laryngorhinootologie 2012;91:27-47.
[PubMed]
7.
Ozer E, Naiboglu B, Meacham R, Ryoo C, Agrawal A, Schuller DE: The value of PET/CT to assess clinically negative necks. Eur Arch Otorhinolaryngol 2012;269:2411-2414.
[PubMed]
8.
Brink I, Klenzner T, Krause T, Mix M, Ross UH, Moser E, Nitzsche EU: Lymph node staging in extracranial head and neck cancer with FDG PET - appropriate uptake period and size-dependence of the results. Nuklearmedizin 2002;41:108-113.
[PubMed]
9.
Rodrigo JP, Suarez C, Ferlito A, Devaney KO, Petruzzelli GJ, Rinaldo A: Potential molecular prognostic markers for lymph node metastasis in head and neck squamous cell carcinoma. Acta Otolaryngol 2003;123:100-105.
[PubMed]
10.
Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 2009;35:699-705.
[PubMed]
11.
Schöder H, Carlson DL, Kraus DH, Stambuk HE, Gönen M, Erdi YE, Yeung HWD, Huvos AG, Shah JP, Larson SM, Wong RJ: 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-762.
[PubMed]
12.
Loo SW, Geropantas K, Beadsmoore C, Montgomery PQ, Martin WM, Roques TW: Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma. Clin Oncol 2011;23:512-517.
[PubMed]
13.
Baumann JE, Michel LS, Chung CH: New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012;24:235-242.
[PubMed]
14.
Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY, Lee SW, Kim SB: Use of 18F FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007;48:752-757.
[PubMed]
15.
Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP: 18F-Fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100:712-720.
[PubMed]
16.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
[PubMed]
17.
Sadick M, Molina F, Frey S, Piniol R, Sadick H, Brade J, Fink C, Schoenberg SO, He Y: Effect of reconstruction parameters in high-definition PET/CT on assessment of lymph node metastases in head and neck squamous cell carcinoma. J Nucl Med Technol 2013;41:19-25.
[PubMed]
18.
Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR, Heilbrun M, Wiggins RH 3rd, Hunt JP, Bentz BG, Hitchcock YJ, Morton KA: Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med 2009;50:1205-1213.
[PubMed]
19.
Schwartz DL, Ragendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K: FDG-PET-prediction of head and neck squamous cell carcinoma outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361-1370.
[PubMed]
20.
Kostareli E, Holzinger D, Hess J: New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Oncol 2012;36:1-10.
[PubMed]
21.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC: Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009;74:1054-1061.
[PubMed]
22.
Paksoy M, Hardal U, Caglar C: Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol 2011;137:1371-1377.
[PubMed]
23.
Chaturvedi AK, Engels EA, Anderson WF, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;10:4294-4301.
[PubMed]
24.
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619.
[PubMed]
25.
Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
[PubMed]
26.
Yavrouian EJ, Sinha UK: Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma. ISRN Surg 2012;2012:715743.
[PubMed]
27.
Mostaan LV, Khorsandi MT, Sharifian SM, Shandiz FH, Mirashrafi F, Sabzari H, Badiee R, Borghei H, Yazdani N: Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: predictive significance or not. Pathol Res Pract 2011;207:448-451.
[PubMed]
28.
Eriksen JG, Steiniche T, Søgaard H, Overgaard J: Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. APMIS 2004;12:560-568.
[PubMed]
29.
Maahs GS, Machado D, Jeckel-Neto EA, Michaelses VS: Cyclin D1 expression and cervical metastases in squamous cell carcinoma of the mouth. Braz J Otorhinolaringol 2007;73:87-94.
[PubMed]
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
